Joshua S. Phillips
Managing Partner @ Catalyst Health Ventures
Norwell, United States
Joshua S. Phillips is a Series A investor at Catalyst Health Ventures in Norwell focused on Medical Device and Medical. Joshua Phillips is the Managing Partner of Catalyst and a member of the Investment Committee. Josh led Catalyst’s investments in Novazyme Pharmaceuticals, Inc. (acquired by Genzyme Corp. NYSE:SNY), BioTrove, Inc. (acquired by Life Technologies Corp. NASDAQ:LIFE), Biocius Life Sciences, Inc. (acquired by Agilent Technologies, Inc. NYSE:A), VortexMedical, Inc. (acquired by Angiodynamics, NASDAQ: ANGO), Allegro Diagnostics, Inc., Pavilion Medical Innovations, Sera Prognostics and Cruzar Medical. He is a Director of Allegro Diagnostics, Hepregen, Pavilion Medical Innovations, Sera Prognostics, Cruzar Medical, Saphena Medical and Kaleidoscope. He was past Chairman of BioTrove, past Director of Biocius Life Sciences and past observer to Novazyme Pharmaceuticals, Inc.Prior to joining Catalyst, Josh was a Manager at the Lucas Group, a boutique strategy-consulting firm, where he led engagements advising healthcare, life science, and technology-based companies. In 1990, Josh co-founded, managed and built a new business unit at Russelectric Inc., a privately held engineering technology firm. In five years, the business achieved annual sales in excess of $5 million and employed 15 engineers and technicians. Josh previously held project and engineering management positions at Pratt & Whitney Aircraft focused on the integration of hardware and software for the control system of the USAF F-22 fighter engine.Josh received a B.E. in Electrical Engineering and Mathematics from Vanderbilt University and an M.B.A. from the Harvard Business School.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 71%
Last updated:
For AI agents: llms.txt
Industries Joshua S. Phillips invests in
Stages Joshua S. Phillips invests in
Countries Joshua S. Phillips invests in
Investment Focus
Industry
- Medical Device 4 (57%)
- Medical 3 (43%)
- Health Care 2 (29%)
- Biotechnology 2 (29%)
- Health Diagnostics 2 (29%)
Stage
- Series A 4 (57%)
- Series B 2 (29%)
- Series C 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Epitel
|
Epitel is a digital health company developing a wearable, wireless EEG monitoring platform to provide accessible, affordable, and reliable for seizure detection. | $26M / Series B / Jul 28, 2026 | |
Esperto Medical
|
Esperto Medical is an Irvine, CA-based medical device company developing next-generation wearable diagnostics that enable hospital-based and remote patient monitoring with unprecedented ease and accuracy. Its unique resonance sonomanometry technology uses acoustic stimulation to directly and noninvasively measure continuous blood pressure withoutcalibration. | Series A / Oct 24, 2024 | |
|
Epitel
|
Epitel is a digital health company developing a wearable, wireless EEG monitoring platform to provide accessible, affordable, and reliable for seizure detection. | $12.5M / Series A / Feb 16, 2022 | |
Conformal Medical
|
Conformal Medical is an early stage medical device company developing devices to prevent stroke in patients with non-valvular atrial fibrillation. The company's proprietary technology will help left atrial appendage closure to meet its true potential. It was founded in 2016 and is headquartered in Nashua, New Hampshire. | $85M / Series C / Aug 06, 2020 | |
|
Conformal Medical
|
Conformal Medical is an early stage medical device company developing devices to prevent stroke in patients with non-valvular atrial fibrillation. The company's proprietary technology will help left atrial appendage closure to meet its true potential. It was founded in 2016 and is headquartered in Nashua, New Hampshire. | $9M / Series B / Dec 03, 2018 | |
Sera Prognostics
|
Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovativediagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. | $19.3M / Series A / Nov 15, 2011 | |
Allegro Diagnostics
|
Allegro Diagnostics was founded in 2006 by Jerome Brody, M.D., and Avrum Spira, M.D., MSc, faculty at the Boston University School of Medicine and thought leaders in the field of pulmonology. The company is currently headquartered in Maynard, Massachusetts. | $4.5M / Series A / Mar 07, 2008 |
Co-Investors
About Catalyst Health Ventures
Catalyst Health Ventures is an early-stage venture capital firm targeting technology solutions applied within the health care and life science industries. At the core of this strategy is a committed, hands-on approach to working with management and syndicate partners to build successful companies. Their disciplined investment process leverages bothintellectual and financial capital to originate deals, cultivate opportunities, and realize the full potential of emerging ventures in the health care and life science marketplace. We seek to invest in companies addressing major global unmet clinical needs in areas such as oncology, cardiovascular disease, obesity, and women’s health. We invest in pioneering and proprietary technological solutions fundamentally designed to reduce treatment costs and improve patient outcomes. By investing in solutions which have a technological foundation of engineering and development such as medical devices, diagnostic tools and instrumentation and consumer healthcare, we minimize the risks related to uncertain scientific experimentation.
Catalyst Health Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Darshana Zaveri
Managing Partner
|
|||
David Mackey
Chief Financial Officer
|
|||
Joshua Phillips
Managing Partner
|
|||
|
Joshua S. Phillips
Managing Partner
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Joshua S. Phillips invest in?
Joshua S. Phillips invests primarily in Medical Device, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Joshua S. Phillips last invest?
The most recent investment recorded for Joshua S. Phillips closed in Jul 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
